Dengue vaccine results prompt both disappointment and hope

The first vaccine against dengue fever to reach large-scale trials has produced mixed results in a phase II study.

Dengue fever is spread by several species of mosquito, including the Asian tiger mosquito | SCIENCE PHOTO LIBRARY
Dengue fever is spread by several species of mosquito, including the Asian tiger mosquito | SCIENCE PHOTO LIBRARY

Researchers expressed surprise over the lower than expected efficacy of the vaccine, but nevertheless hailed the demonstration that a vaccine against dengue fever is possible as a 'breakthrough'.

Dengue fever is a mosquito-borne viral disease for which there is currently no specific treatment or vaccine. Consequently, cases are managed with supportive measures. Approximately half the world's population lives in countries where dengue fever is endemic.

In the phase II study, 4,002 Thai children aged 4 to 11 years were randomised to receive either the experimental dengue vaccine or control (rabies vaccine or placebo) at 0, 6 and 12 months. 

Overall vaccine efficacy in the per-protocol analysis (n=3,673) was 30.2%, with statistically significant efficacy reported for dengue virus serotypes (DENV) 1, 3 and 4 after at least one injection (61.2%, 81.9% and 90%, respectively) but not after three injections. However, efficacy against DENV2, which accounted for 59% of episodes, was not shown.

Dengue vaccine was well tolerated, with no reported vaccine-related serious adverse events or other safety signals after two years of active follow-up.

The vaccine, developed by Sanofi Pasteur MSD and known as CYD-TDV, is a recombinant, live attenuated, tetravalent vaccine based on the yellow fever 17D vaccine strain.

Two randomised controlled phase III trials of the vaccine involving more than 30,000 children are currently underway in Asia and Latin America. They are designed to assess its efficacy in preventing symptomatic virologically confirmed dengue cases, regardless of severity or serotype.

The Asian trial is recruiting children aged 2 to 14 years and is expected to complete in July 2014. The Latin American trial has enrolled children aged 9 to 16 years and has an anticipated finish date of August 2016.

Travel health factsheet on dengue fever

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)